Product Program year 2025 Source: CMS Open Payments

Quviviq

Drug Insomnia

NDC 80491-7850-3

Open in the dashboard

General payments

$6,730,091

116,237 payments

Research payments

$4,539,568

474 payments

Through program year 2025, $6,730,091 in general payments and $4,539,568 in research payments were reported against Quviviq (Insomnia).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

8 rows
Year Kind Amount Payments
2025 General $90,981 2,286
2025 Research $811,479 124
2024 General $905,179 20,639
2024 Research $618,183 96
2023 General $4,778,199 76,059
2023 Research $2,961,776 244
2022 General $955,731 17,253
2022 Research $148,130 10

Breakdown

Who paid General payments · program years 2022–2025
  1. Idorsia Pharmaceuticals US Inc $6,730,091 116,237 payments
Top recipients General payments · program year 2025
  1. Suzanne Bertisch Sleep Medicine · Boston, MA $18,960 21% · 6 payments
  2. David Neubauer Psychiatry · Baltimore, MD $9,544 10% · 2 payments
  3. Hari Sachs Pediatrics · Rockville, MD $6,400 7% · 4 payments
  4. William McCall Psychiatry · Augusta, GA $3,509 4% · 3 payments
  5. Abhinav Singh Internal Medicine · Greenwood, IN $1,890 2% · 1 payment

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Sleep Medicine Internal Medicine $21,012 23% · 21 practitioners
  2. Psychiatry Psychiatry & Neurology $19,127 21% · 233 practitioners
  3. Nurse Practitioner, Psychiatric/Mental Health Nurse Practitioner $9,348 10% · 359 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $7,081 8% · 292 practitioners
  5. Pediatrics $6,543 7% · 6 practitioners

The top 5 of 65 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Massachusetts $20,843 23% · 8 recipients
  2. Maryland $17,173 19% · 35 recipients
  3. Georgia $8,515 9% · 164 recipients
  4. Texas $7,861 9% · 326 recipients
  5. Indiana $3,394 4% · 67 recipients

The top 5 of 44 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

19,726

Prescriptions dispensed, refills included

Drug cost

$9,836,103

Paid at the pharmacy, in all

Prescribers

1,125

With 11 or more claims of it

Medicare Part D drugs matched to QUVIVIQ, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Quviviq Daridorexant Hcl Same name 1,125 19,726 $9,836,103

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Michael Miller General Surgery IN 128 $63,371 $15
Royle Eenigenburg Psychiatry WI 107 $50,603 $36
Taylor Szucs Physician Assistant NC 86 $43,195 $60
Sarang Patel Physician Assistant MI 82 $39,599 None on record
Henry Emerle Psychiatry IA 80 $40,202 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
116,237 general · 474 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record